Cargando…
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
BACKGROUND AND AIM: This study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort. METHODS: This multicenter study was conducted b...
Autores principales: | Mashiba, Toshie, Joko, Kouji, Kurosaki, Masayuki, Ochi, Hironori, Osaki, Yukio, Kojima, Yuji, Nakata, Ryo, Goto, Tohru, Takehiro, Akahane, Kimura, Hiroyuki, Mitsuda, Akeri, Kawanami, Chiharu, Uchida, Yasushi, Ogawa, Chikara, Kusakabe, Atsunori, Narita, Ryuichi, Ide, Yasushi, Abe, Takehiko, Tsuji, Keiji, Kitamura, Tadashi, Okada, Kazuhiko, Sohda, Tetsuro, Shigeno, Masaya, Satou, Takashi, Izumi, Namiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901785/ https://www.ncbi.nlm.nih.gov/pubmed/29659591 http://dx.doi.org/10.1371/journal.pone.0194704 |
Ejemplares similares
-
Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2019) -
Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022) -
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
por: Tsuchiya, Kaoru, et al.
Publicado: (2021) -
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016) -
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
por: Yasui, Yutaka, et al.
Publicado: (2022)